Taichang Zhang

机构：BeiGene (China)

发表论文 6 篇 · 总被引 93 次 · h-index 5

代表论文

• Discovery of the Clinical Candidate Sonrotoclax (BGB-11417), a Highly Potent and Selective Inhibitor for Both WT and G101V Mutant Bcl-2 (2024 · Journal of Medicinal Chemistry · 被引 50)
• Abstract 3077: Preclinical characterization of BGB-11417, a potent and selective Bcl-2 inhibitor with superior antitumor activities in haematological tumor models (2020 · Cancer Research · 被引 19)
• Translational modelling to predict human pharmacokinetics and pharmacodynamics of a Bruton's tyrosine kinase‐targeted protein degrader BGB‐16673 (2024 · British Journal of Pharmacology · 被引 12)
• Discovery of BGB-8035, a Highly Selective Covalent Inhibitor of Bruton’s Tyrosine Kinase for B-Cell Malignancies and Autoimmune Diseases (2023 · Journal of Medicinal Chemistry · 被引 7)
• A highly selective PI3Kδ inhibitor BGB-10188 shows superior preclinical anti-tumor activities and decreased on-target side effects on colon (2024 · Neoplasia · 被引 5)
• Abstract 3778: Preclinical evaluation of BG-C137, a potential first-in-class FGFR2b-targeting ADC, for the treatment of FGFR2b-expressing cancer (2025 · Cancer Research)